<DOC>
	<DOCNO>NCT01331746</DOCNO>
	<brief_summary>A study look effectiveness drug call APD515 , design apply line inside mouth , relieve dryness mouth . Study compare one week treatment APD515 one week treatment match placebo see good effect patient 's mouth dryness , accord score .</brief_summary>
	<brief_title>Proof-of-concept ( PoC ) Study APD515</brief_title>
	<detailed_description />
	<mesh_term>Xerostomia</mesh_term>
	<criteria>Aged ≥ 18 year Able willing give write informed consent . Confirmed primary neoplasm site ( apart nonmelanoma skin cancer ) , firstline cytotoxic therapy complete one month prior study entry . Ongoing palliative , hormonal , cytostatic `` target '' ( e.g. , monoclonal antibody , tyrosine kinase inhibitor , etc ) therapy permit , provide risk oral mucositis subject judge significant . Subjective complaint dry mouth , ongoing least two week prior study entry . Capacity salivary stimulation , demonstrate stimulated whole saliva flow rate &gt; unstimulated whole saliva flow rate . Karnofsky performance score ≥ 60 % ECOG performance status ≤ 2 . Adequate renal hepatic function hydration status : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 * upper limit normal ( ULN ) ; Serum urea &lt; 1.5 * ULN serum urea : creatinine ratio &lt; 100 ( urea creatinine express unit ) ; Plasma sodium ≤ ULN . Adequate haematological function : Haemoglobin ≥ 9 g/dL ; White blood count ≥ 1.0 * 10^9/L ; Platelet count ≥ 50 *x 10^9/L . For female childbearing potential : ability willingness use highly effective form contraception ( e.g. , abstinence sexual intercourse , surgical sterilisation ( subject partner ) doublebarrier method contraception either intrauterine device ( IUD ) occlusive cap spermicide , conjunction partner 's use condom ) study period least 48 hour afterwards . Confirmed diagnosis Sjögren 's syndrome . Prior radiotherapy head &amp; neck cancer , substantial dos radiation deliver area mouth salivary gland . Significant , symptomatic disease oral cavity , include oral candidosis oral mucositis . Allergy active ingredient excipients APD515 . Use oral topical ( include ocular ) pilocarpine cevimeline two week prior enrolment . Concomitant use procainamide , quinidine ganglionic block agent mecamylamine , pentolinium trimethaphan . Intestinal urinary obstruction . Myocardial infarction intestinal anastomosis within previous 6 month . Participation investigational drug device study within 1 month prior study entry . For female subject , positive pregnancy test . Any condition disease detect medical interview/physical examination would render subject unsuitable study , place subject undue risk interfere ability subject complete study opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>